PubRank

George J Weiner

Author PubWeight™ 59.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer immunotherapy comes of age. J Clin Oncol 2011 5.87
2 Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009 2.75
3 Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 2010 2.06
4 Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet 2013 1.85
5 Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 2010 1.83
6 Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006 1.79
7 Cancer and inflammation: promise for biologic therapy. J Immunother 2010 1.72
8 Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2011 1.71
9 NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2007 1.69
10 CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005 1.62
11 B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005 1.49
12 Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007 1.47
13 Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011 1.47
14 Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 2006 1.44
15 A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008 1.36
16 B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006 1.25
17 Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother 2007 1.24
18 CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008 1.14
19 Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2004 1.13
20 Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 2009 1.13
21 CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 2003 1.07
22 GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma 2013 1.05
23 AACR Cancer Progress Report 2014. Clin Cancer Res 2014 1.05
24 A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J Pharm Sci 2007 1.01
25 The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics 2006 1.00
26 AACR Cancer Progress Report 2013. Clin Cancer Res 2013 0.95
27 Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol 2011 0.93
28 CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr Opin Oncol 2003 0.91
29 CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr Opin Investig Drugs 2003 0.91
30 Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma. J Cell Biochem 2012 0.89
31 Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol 2012 0.87
32 Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am J Hematol 2014 0.86
33 Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Semin Oncol 2003 0.85
34 CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv Drug Deliv Rev 2009 0.84
35 A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol 2013 0.84
36 Picking the optimal target for antibody-drug conjugates. Am Soc Clin Oncol Educ Book 2013 0.83
37 CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother 2005 0.83
38 Measuring granulocyte and monocyte accumulation at malignant lymphoma sites. J Clin Oncol 2008 0.82
39 Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J 2014 0.82
40 Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. Am J Hematol 2014 0.81
41 CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother 2013 0.80
42 Phosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes. J Immunol Methods 2005 0.80
43 CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells. Int Immunol 2004 0.79
44 Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immunol Immunother 2003 0.78
45 Short telomeres in B-CLL: the chicken or the egg? Blood 2008 0.78
46 Complement in monoclonal antibody therapy of cancer. Immunol Res 2014 0.78
47 Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. Semin Oncol 2002 0.78
48 Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. Leuk Lymphoma 2014 0.77
49 Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. Semin Oncol 2002 0.75
50 Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia. Oligonucleotides 2005 0.75
51 Persistent thrombocytopenia during remission in acute leukemia does not preclude long-term disease-free survival. Am J Hematol 2002 0.75